Literature DB >> 1839300

In vitro testing of clarithromycin in combination with ethambutol and rifampicin against Mycobacterium avium complex.

F Stauffer1, O Dörtbudak, E Lahonik.   

Abstract

The activity of clarithromycin in combination with ethambutol and rifampicin was tested at concentrations achievable in serum against 20 strains of Mycobacterium avium complex. The combination of clarithromycin plus rifampicin showed inhibition of 11 of the strains and bactericidal synergism against seven of the strains. When ethambutol was added, a bactericidal effect was observed against 16 strains. On the basis of these in vitro data it seems that clarithromycin in combination with rifampicin and ethambutol may be a promising drug for the effective treatment of infections caused by M. avium complex.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1839300     DOI： 10.1007/bf01645362

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  20 in total

Review 1.  Mycobacterium avium complex infection in the acquired immunodeficiency syndrome.

Authors:  C R Horsburgh
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

2.  In vitro and in vivo activity of azithromycin (CP 62,993) against the Mycobacterium avium complex.

Authors:  C B Inderlied; P T Kolonoski; M Wu; L S Young
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

3.  Ethambutol: a key for Mycobacterium avium complex chemotherapy?

Authors:  G Källenius; S B Svenson; S E Hoffner
Journal:  Am Rev Respir Dis       Date:  1989-07

4.  Qualitative and quantitative drug-susceptibility tests in mycobacteriology.

Authors:  L Heifets
Journal:  Am Rev Respir Dis       Date:  1988-05

5.  Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents.

Authors:  D M Yajko; P S Nassos; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

6.  Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis.

Authors:  L Heifets; P Lindholm-Levy
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

7.  Infections caused by Mycobacterium avium complex in immunocompromised patients: diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristics.

Authors:  T E Kiehn; F F Edwards; P Brannon; A Y Tsang; M Maio; J W Gold; E Whimbey; B Wong; J K McClatchy; D Armstrong
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

8.  Mycobacterium avium-M. intracellulare isolates from patients with or without acquired immunodeficiency syndrome.

Authors:  C R Horsburgh; D L Cohn; R B Roberts; H Masur; R A Miller; A Y Tsang; M D Iseman
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

9.  Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellulare complex.

Authors:  A M Hunter; I A Campbell; P A Jenkins; A P Smith
Journal:  Thorax       Date:  1981-05       Impact factor: 9.139

10.  Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects.

Authors:  L B Heifets; M D Iseman; P J Lindholm-Levy
Journal:  Am Rev Respir Dis       Date:  1988-03
View more
  7 in total

1.  Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination.

Authors:  Irma A J M Bakker-Woudenberg; Wim van Vianen; Dick van Soolingen; Henri A Verbrugh; Michiel A van Agtmael
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

Review 2.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

3.  Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex.

Authors:  N Rastogi; K S Goh; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

4.  In vitro susceptibility of Mycobacterium ulcerans to clarithromycin.

Authors:  F Portaels; H Traore; K De Ridder; W M Meyers
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

Review 5.  The Mycobacterium avium complex.

Authors:  C B Inderlied; C A Kemper; L E Bermudez
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

Review 6.  The new macrolides. Azithromycin and clarithromycin.

Authors:  M S Kanatani; B J Guglielmo
Journal:  West J Med       Date:  1994-01

7.  French multicenter study involving eight test sites for radiometric determination of activities of 10 antimicrobial agents against Mycobacterium avium complex.

Authors:  N Rastogi; R M Bauriaud; A Bourgoin; B Carbonnelle; C Chippaux; M J Gevaudan; K S Goh; D Moinard; P Roos
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.